Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy.

Abstract:

:Checkpoint inhibition has established immunotherapy as a major modality of cancer treatment. However, the success of cancer immunotherapy is still limited as immune regulation of tumor immunity is very complicated and mechanisms involved may also differ among cancer types. Beside checkpoints, other good candidates for immunotherapy are immunosuppressive cytokines. TGF-β is a very potent immunosuppressive cytokine involved in suppression of tumor immunity and also necessary for the function of some regulatory cells. TGF-β has three isoforms, TGF-β 1, 2 and 3. It has been demonstrated in multiple mouse tumor models that inhibition of all three isoforms of TGF-β facilitates natural tumor immunosurveillance and tumor vaccine efficacy. However, individual isoforms of TGF-β are not well studied yet. Here, by using monoclonal antibodies (mAbs) specific for TGF-β isoforms, we asked whether it is necessary to inhibit TGF-β3 to enhance tumor immunity. We found that blockade of TGF-β1 and 2 and of all isoforms provided similar effects on tumor natural immunosurveillance and therapeutic vaccine-induced tumor immunity. The protection was CD8+ T cell-dependent. Blockade of TGF-β increased vaccine-induced Th1-type response measured by IFNγ production or T-bet expression in both tumor draining lymph nodes and tumors, although it did not increase tumor antigen-specific CD8+ T cell numbers. Therefore, protection correlated with qualitative rather than quantitative changes in T cells. Furthermore, when combined with PD-1 blockade, blockade of TGF-β1 and 2 further increased vaccine efficacy. In conclusion, blocking TGF-β1 and 2 is sufficient to enhance tumor immunity, and it can be further enhanced with PD-1 blockade.

journal_name

Oncoimmunology

journal_title

Oncoimmunology

authors

Terabe M,Robertson FC,Clark K,De Ravin E,Bloom A,Venzon DJ,Kato S,Mirza A,Berzofsky JA

doi

10.1080/2162402X.2017.1308616

subject

Has Abstract

pub_date

2017-03-31 00:00:00

pages

e1308616

issue

5

eissn

2162-4011

issn

2162-402X

pii

1308616

journal_volume

6

pub_type

杂志文章
  • The immune molecular landscape of the B7 and TNFR immunoregulatory ligand-receptor families in head and neck cancer: A comprehensive overview and the immunotherapeutic implications.

    abstract::The B7 family and tumor necrosis factor receptor (TNFR) superfamily play a vital role in the T-cell co-stimulatory and co-inhibitory pathways, regulating T-cell activation, tolerance, and exhaustion; therapeutic modulation of these pathways is translated into effective new cancer treatments. Better understanding of th...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1288329

    authors: Chen YP,Zhang J,Wang YQ,Liu N,He QM,Yang XJ,Sun Y,Ma J

    更新日期:2017-02-16 00:00:00

  • Mammaglobin-A is a target for breast cancer vaccination.

    abstract::We recently completed a phase 1 clinical trial demonstrating the safety of a mammaglobin-A DNA vaccine in patients with metastatic breast cancer. We are currently enrolling patients with early stage breast cancer in a phase 1b clinical trial. The mammaglobin-A DNA vaccine will be administered concurrently with neoadju...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1069940

    authors: Kim SW,Goedegebuure P,Gillanders WE

    更新日期:2016-02-26 00:00:00

  • Subverting the adaptive immune resistance mechanism to improve clinical responses to immune checkpoint blockade therapy.

    abstract::The correlation between tumor-infiltrating lymphocyte (TIL)-expression of programmed cell death ligand 1 (PD-L1) and clinical responsiveness to the PD-1 blocking antibody nivolumab implicates adaptive immune evasion mechanisms in cancer. We review our findings that tumor cell PD-L1 expression is induced by interferon ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/21624011.2014.954868

    authors: Kim YJ

    更新日期:2015-01-07 00:00:00

  • The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers.

    abstract::Analysis of PDL1 mRNA expression in ∼5,500 breast cancers showed PDL1 upregulation in 38% of basal tumors and 38% of inflammatory breast cancers (IBC). Upregulation, associated with signs of strong cytotoxic local immune response, was associated with a better survival in the basal or triple-negative subtypes, and with...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1085148

    authors: Bertucci F,Finetti P,Birnbaum D,Mamessier E

    更新日期:2015-08-31 00:00:00

  • Development and validation of an immune-related gene pairs signature in colorectal cancer.

    abstract::Although the outcome of colorectal cancer (CRC) patients has improved significantly with the recent implementation of annual screening programs, reliable prognostic biomarkers are still needed due to the disease heterogeneity. Increasing pieces of evidence revealed an association between immune signature and CRC progn...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2019.1596715

    authors: Wu J,Zhao Y,Zhang J,Wu Q,Wang W

    更新日期:2019-04-15 00:00:00

  • Procarcinogenic regulatory T cells in microbial-induced colon cancer.

    abstract::Regulatory T cell (Treg) promote IL-17-mediated colon tumorigenesis in multiple intestinal neoplasia (Min) mice colonized with enterotoxigenic Bacteroides fragilis (ETBF). Although they retain their immunosuppressive function, mucosal Treg are instrumental to initiate ETBF-triggered IL-17 colitis by limiting the avail...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1118601

    authors: Geis AL,Housseau F

    更新日期:2015-12-21 00:00:00

  • Transforming the prostatic tumor microenvironment with oncolytic virotherapy.

    abstract::Prostate cancer (PCa) was estimated to have the second highest global incidence rate for male non-skin tumors and is the fifth most deadly in men thus mandating the need for novel treatment options. MG1-Maraba is a potent and versatile oncolytic virus capable of lethally infecting a variety of prostatic tumor cell lin...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1445459

    authors: Atherton MJ,Stephenson KB,Tzelepis F,Bakhshinyan D,Nikota JK,Son HH,Jirovec A,Lefebvre C,Dvorkin-Gheva A,Ashkar AA,Wan Y,Stojdl DF,Belanger EC,Breau RH,Bell JC,Saad F,Singh SK,Diallo JS,Lichty BD

    更新日期:2018-03-27 00:00:00

  • Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy.

    abstract::Depending on tumor type, stage and immunological contexture, the inhibition of chemokines or their receptors may yield positive or deleterious effects on disease progression. We have recently demonstrated in several murine models of anthracycline-based chemotherapy that the inhibition of chemokine (C-C motif) ligand 2...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.27663

    authors: Ma Y,Adjemian S,Galluzzi L,Zitvogel L,Kroemer G

    更新日期:2014-01-01 00:00:00

  • The Helicobacter pylori HopQ outermembrane protein inhibits immune cell activities.

    abstract::We previously showed that the colorectal cancer colonizing bacterium Fusobacterium nucleatum protects tumors from immune cell attack via binding of the fusbacterial Fap2 outer-membrane protein to TIGIT, a checkpoint inhibitory receptor expressed on T cells and NK cells. Helicobacter pylori, the causative agent for pep...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1553487

    authors: Gur C,Maalouf N,Gerhard M,Singer BB,Emgård J,Temper V,Neuman T,Mandelboim O,Bachrach G

    更新日期:2019-01-29 00:00:00

  • BRAF V600E mutation correlates with suppressive tumor immune microenvironment and reduced disease-free survival in Langerhans cell histiocytosis.

    abstract::Langerhans cell histiocytosis (LCH) is a neoplasm of myeloid origin characterized by a clonal proliferation of CD1a(+)/CD207(+) dendritic cells. Recurrent BRAF V600E mutation has been reported in LCH. In the present report, we confirm the feasibility of the high-specificity monoclonal antibody VE1 for detecting BRAF V...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1185582

    authors: Zeng K,Wang Z,Ohshima K,Liu Y,Zhang W,Wang L,Fan L,Li M,Li X,Wang Y,Yu Z,Yan Q,Guo S,Wei J,Guo Y

    更新日期:2016-06-14 00:00:00

  • Bioreactors get personal.

    abstract::Adoptive cell transfer immunotherapy against melanoma is highly effective. However, this therapy has seen limited dissemination, mainly due to the complexity and costs of cell expansion protocols. Two bioreactors have recently been described that simplify and streamline the production of individualized cell therapies....

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.21206

    authors: Somerville RP,Dudley ME

    更新日期:2012-11-01 00:00:00

  • Complete response in patients with locally advanced rectal cancer after neoadjuvant treatment with nivolumab.

    abstract::Introduction: PD-1 inhibitors have been approved for the treatment of dMMR patients with metastatic colorectal cancer, but the efficacy of neoadjuvant treatment with PD-1 in dMMR locally advanced rectal cancer (LARC) patients has not yet been defined. Patients and methods: Two patients with LARC received Nivolumab as ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2019.1663108

    authors: Zhang J,Cai J,Deng Y,Wang H

    更新日期:2019-09-19 00:00:00

  • CD44v3 protein-carrying tumor-derived exosomes in HNSCC patients' plasma as potential noninvasive biomarkers of disease activity.

    abstract::The molecular cargo of tumor-cell-derived exosomes (TEX) mimics that of parental tumor cells. Thus, TEX could potentially serve as noninvasive biomarkers of cancer progression. However, separation of TEX from non-TEX in patients' plasma requires tumor antigen-specific detection reagents. CD44v3 has been of interest as...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1747732

    authors: Theodoraki MN,Matsumoto A,Beccard I,Hoffmann TK,Whiteside TL

    更新日期:2020-04-07 00:00:00

  • Radiotherapy supports protective tumor-specific immunity.

    abstract::Radiotherapy is an important therapeutic option for the treatment of cancer. Growing evidence indicates that, besides inducing an irreversible DNA damage, radiotherapy promotes tumor-specific immune response, which significantly contribute to therapeutic efficacy. We postulate that radiotherapy activates tumor-associa...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.21478

    authors: Gupta A,Sharma A,von Boehmer L,Surace L,Knuth A,van den Broek M

    更新日期:2012-12-01 00:00:00

  • eIF2α phosphorylation: A hallmark of immunogenic cell death.

    abstract::Immunogenic cell death (ICD) induced by anticancer chemotherapeutics is usually preceded by premortem stress affecting the endoplasmic reticulum (ER). This ER stress does not reflect a canonical unfolded protein response (UPR) but rather manifests solely at the level of the phosphorylation of eIF2α. eIF2α phosphorylat...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1431089

    authors: Bezu L,Sauvat A,Humeau J,Leduc M,Kepp O,Kroemer G

    更新日期:2018-02-14 00:00:00

  • TLR4 signaling induces the release of microparticles by tumor cells that regulate inflammatory cytokine IL-6 of macrophages via microRNA let-7b.

    abstract::Tumor cells expressing TLRs is generally recognized to mediate tumor inflammation. However, whether and how tumor TLR signaling pathways negatively regulate tumor inflammation remains unclear. In this report, we find that TLR4 signaling of H22 hepatocarcinoma tumor cells is transduced through MyD88 pathway to actin cy...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.19854

    authors: Li D,Jia H,Zhang H,Lv M,Liu J,Zhang Y,Huang T,Huang B

    更新日期:2012-08-01 00:00:00

  • Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer.

    abstract::Background. Immunotherapy has shown efficacy in small cell lung cancer (SCLC), but only a subset of patients benefits. Surrogate biomarkers are urgently needed. Our aim was to evaluate serum Th1, Th2, and proinflammatory cytokines in two cohorts of SCLC patients before and during treatment with chemotherapy with or wi...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2019.1593810

    authors: Hardy-Werbin M,Rocha P,Arpi O,Taus Á,Nonell L,Durán X,Villanueva X,Joseph-Pietras D,Nolan L,Danson S,Griffiths R,Lopez-Botet M,Rovira A,Albanell J,Ottensmeier C,Arriola E

    更新日期:2019-03-27 00:00:00

  • Flipping the script on macrophages in leiomyosarcoma.

    abstract::Macrophages promote the growth of leiomyosarcoma (LMS), a malignant soft-tissue tumor. CD47 on tumor cells binds to the macrophagic receptor signal regulatory protein α (SIRPα) and prevents phagocytosis. We showed that anti-CD47 monoclonal antibodies (mAbs) allow macrophages to engulf LMS cells and prevent tumor growt...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.20799

    authors: Edris B,Weiskopf K,Weissman IL,van de Rijn M

    更新日期:2012-10-01 00:00:00

  • HDAC inhibitors and their potential applications to glioblastoma therapy.

    abstract::Natural killer (NK) cells are integral components of the antitumor immune response. The downregulation of ligands for NK-cell stimulatory receptors represents a strategy whereby glioblastoma cells can evade NK-cell attacks. Histone deacetylase inhibitors can stimulate the (re)expression of these ligands, driving cytot...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.25219

    authors: Adamopoulou E,Naumann U

    更新日期:2013-08-01 00:00:00

  • Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment.

    abstract::Oncolytic virotherapy is an emergent promising therapeutic approach for the treatment of cancer. We have constructed a vaccinia virus (WR strain) deleted for thymidine kinase (TK) and ribonucleotide reductase (RR) genes that expressed the fusion suicide gene FCU1 derived from the yeast cytosine deaminase and uracil ph...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1080414

    authors: Fend L,Remy-Ziller C,Foloppe J,Kempf J,Cochin S,Barraud L,Accart N,Erbs P,Fournel S,Préville X

    更新日期:2015-10-06 00:00:00

  • Strategies for purging CD96+ stem cells in vitro and in vivo: New avenues for autologous stem cell transplantation in acute myeloid leukemia.

    abstract::The persistence of leukemic stem cells (LSCs) in acute myeloid leukemia (AML) patients receiving chemotherapy may be responsible for the high frequency of relapse. The selective elimination of CD96+ AML-LSCs by means of CD96-specific monoclonal antibodies may be a promising therapeutic approach and revitalize autologo...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.24500

    authors: Staudinger M,Humpe A,Gramatzki M

    更新日期:2013-06-01 00:00:00

  • High-throughput T cell receptor sequencing reveals distinct repertoires between tumor and adjacent non-tumor tissues in HBV-associated HCC.

    abstract::T lymphocytes, which recognize antigen peptides through specific T cell receptors (TCRs), play an important role in the human adaptive immune response. TCR diversity is closely associated with host immune response and cancer prognosis. Although tumor-infiltrating T lymphocytes have implications for tumor prognosis, fe...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1219010

    authors: Chen Y,Xu Y,Zhao M,Liu Y,Gong M,Xie C,Wu H,Wang Z

    更新日期:2016-08-05 00:00:00

  • PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system?

    abstract::The programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) pathway has emerged as a critical inhibitory pathway regulating T-cell response in non-small-cell lung cancer (NSCLC), and the development of PD-1/PD-L1 inhibitors has changed the landscape of NSCLC therapy. Nevertheless, the high degree of non-responders demons...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1315488

    authors: Raimondi C,Carpino G,Nicolazzo C,Gradilone A,Gianni W,Gelibter A,Gaudio E,Cortesi E,Gazzaniga P

    更新日期:2017-04-20 00:00:00

  • Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy.

    abstract::Gamma delta T cells (γδT) are potent mediators of antitumor cytotoxicity and have shown promising efficacy in early phase clinical trials. Most is known about the tumoricidal properties of cells bearing the Vδ2 T cell receptor chain, but recent studies have demonstrated that cells with the Vδ1 chain and those with nei...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/2162402X.2014.973808

    authors: Fisher J,Kramer AM,Gustafsson K,Anderson J

    更新日期:2014-12-23 00:00:00

  • IL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells.

    abstract::The functional status of CD4(+) T cells is a critical determinant of antitumor immunity. Polyfunctional CD4(+) T cells possess the ability to concomitantly produce multiple Th1-type cytokines, exhibiting a functional attribute desirable for cancer immunotherapy. However, the mechanisms by which these cells are induced...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1171445

    authors: Ding ZC,Liu C,Cao Y,Habtetsion T,Kuczma M,Pi W,Kong H,Cacan E,Greer SF,Cui Y,Blazar BR,Munn DH,Zhou G

    更新日期:2016-04-25 00:00:00

  • Local Salmonella immunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumor.

    abstract::The efficacy of antitumoral responses can be increased using combinatorial vaccine strategies. We recently showed that vaccination could be optimized by local administration of diverse molecular or bacterial agents to target and augment antitumoral CD8 T cells in the genital mucosa (GM) and increase regression of cerv...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1016697

    authors: Domingos-Pereira S,Hojeij R,Reggi E,Derré L,Chevalier MF,Romero P,Jichlinski P,Nardelli-Haefliger D

    更新日期:2015-05-22 00:00:00

  • Ecrg4 contributes to the anti-glioma immunosurveillance through type-I interferon signaling.

    abstract::Esophageal cancer-related gene 4 (Ecrg4), a hormone-like peptide, is thought to be a tumor suppressor, however, little is known about the mechanism of how Ecrg4 suppresses tumorigenesis. Here, we show that the ecrg4 null glioma-initiating cell (GIC) line, which was generated from neural stem cells of ecrg4 knockout (K...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1242547

    authors: Moriguchi T,Kaneumi S,Takeda S,Enomoto K,Mishra SK,Miki T,Koshimizu U,Kitamura H,Kondo T

    更新日期:2016-10-14 00:00:00

  • Co-localization of CD169+ macrophages and cancer cells in lymph node metastases of breast cancer patients is linked to improved prognosis and PDL1 expression.

    abstract::Breast cancer is the most common form of cancer in women worldwide. Although the survival among breast cancer patients has improved, there is still a large group of patients with dismal prognosis. One of the most important prognostic factors for poor prognosis is lymph node metastasis. Increasing knowledge concerning ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1848067

    authors: Björk Gunnarsdottir F,Auoja N,Bendahl PO,Rydén L,Fernö M,Leandersson K

    更新日期:2020-11-22 00:00:00

  • Human CD4- invariant NKT lymphocytes regulate graft versus host disease.

    abstract::Despite increasing evidence for a protective role of invariant (i) NKT cells in the control of graft-versus-host disease (GVHD), the mechanisms underpinning regulation of the allogeneic immune response in humans are not known. In this study, we evaluated the distinct effects of human in vitro expanded and flow-sorted ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1470735

    authors: Coman T,Rossignol J,D'Aveni M,Fabiani B,Dussiot M,Rignault R,Babdor J,Bouillé M,Herbelin A,Coté F,Moura IC,Hermine O,Rubio MT

    更新日期:2018-08-23 00:00:00

  • Tumor evasion of humoral immunity mediated by proteolytic impairment of antibody triggered immune effector function.

    abstract::Immune suppression is recognized as a hallmark of cancer and this notion is largely based on studies on cellular immunity. Our recent studies have demonstrated a potential new mechanism of cancer suppression of immunity by impairment of antibody effector function mediated by proteolytic enzymes in the tumor microenvir...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1122861

    authors: Zhang N,Jordan RE,An Z

    更新日期:2015-12-29 00:00:00